Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single-Arm, Multicenter Clinical Study of Induction Chemotherapy Combined With Tislelizumab as Neoadjuvant Therapy for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

NCT07370337 is registered in ClinicalTrials.gov with Eye & ENT Hospital of Fudan University as lead sponsor.

NCT NCT07370337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07370337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single-Arm, Multicenter Clinical Study of Induction Chemotherapy Combined With Tislelizumab as Neoadjuvant Therapy for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal
Lead sponsor
Eye & ENT Hospital of Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
May 12, 2025
Completion date
December 31, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced tumor, squamous cell carcinoma of external auditory canal